SGP

SpyGlass Pharma, Inc.
CAPPED RATING

SpyGlass Pharma, Inc. (SGP) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D+). The rating has held at C for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
B
Factor Score 3.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -11.0
EV / EBITDA -11.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 27.5%
Price Return 12M 24.6%
Catalyst Signal 0.00
Market Cap $1.1B
TTM Revenue N/A
Price / Sales N/A
ROE -43.0%

Historical Factor Score Progression

Held C for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) D+ (1.6) C- (2.0) B (3.4) C+ (2.6) C (2.4)
2026-11-07 C+ (2.5) D+ (1.6) D- (0.8) B (3.4) C+ (2.7) C (2.2)
2026-10-31 C+ (2.5) D+ (1.5) D- (0.8) B+ (3.5) C+ (2.7) C (2.2)
2026-10-24 C+ (2.5) D+ (1.5) D- (0.8) B (3.5) C+ (2.6) C (2.2)
2026-10-17 C+ (2.5) D+ (1.5) D- (0.8) B (3.4) C+ (2.6) C (2.2)
Page 1 of 4